[Skip to Content]
[Skip to Content Landing]
Views 269
Citations 0
Comment & Response
May 7, 2020

De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ—Reply

Author Affiliations
  • 1Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2Dana-Farber Cancer Center, Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts
JAMA Oncol. Published online May 7, 2020. doi:10.1001/jamaoncol.2020.0819

In Reply We thank Hwang and colleagues for their views on the nonoperative management of ductal carcinoma in situ (DCIS) provided in response to our Viewpoint on the de-escalation of breast cancer surgery.1 This is an area of great controversy with many conflicting studies. We concur that there are some invasive carcinomas that are indolent and unlikely to cause problems during a woman’s lifetime. Unfortunately, at this time we are unable to identify these indolent cancers. In the randomized clinical trials of patients with an initial diagnosis of DCIS performed by the National Surgical Adjuvant Breast and Bowel Project2 and the European Organisation for Research and Treatment of Cancer,3 development of an invasive recurrence resulted in decreased breast cancer–specific survival, suggesting a possible risk associated with backing off on therapy. In patients with stage I hormone receptor–positive cancers enrolled in the randomized clinical trials of tamoxifen in the Early Breast Cancer Trialists’ Collaborative Group overview,4 the 15-year mortality after 5 years of tamoxifen treatment was 13%, emphasizing that even small hormone receptor–positive cancers have definite metastatic potential.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×